Challenges in multiple myeloma diagnosis and treatment.

about

Challenges in multiple myeloma diagnosis and treatment.

Item

http://www.wikidata.org/entity/Q36852225

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Challenges in multiple myeloma diagnosis and treatment.

@en

type

Item

label

Challenges in multiple myeloma diagnosis and treatment.

@en

prefLabel

Challenges in multiple myeloma diagnosis and treatment.

@en

P1476

Challenges in multiple myeloma diagnosis and treatment.

@en

P2093

N C Munshi

http://www.w3.org/2001/XMLSchema#string

S Girnius

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.

P2888

leusup.2013.2

P304

S3-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1038/LEUSUP.2013.2

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260174288

http://www.w3.org/2001/XMLSchema#string

P698

27175259

http://www.w3.org/2001/XMLSchema#string

P932

4851186

http://www.w3.org/2001/XMLSchema#string

Challenges in multiple myeloma diagnosis and treatment.

about

Challenges in multiple myeloma diagnosis and treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P932